Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World

JAMA Oncol. 2017 Jul 1;3(7):889-890. doi: 10.1001/jamaoncol.2016.5296.

Authors

Sham Mailankody¹, Vinay Prasad²

Affiliations

¹ Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
² Division of Hematology Oncology, Knight Cancer Institute, Portland, Oregon3Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland.

PMID: 27892992
DOI: 10.1001/jamaoncol.2016.5296

No abstract available

MeSH terms

Antineoplastic Agents / therapeutic use*
Biomarkers
Clinical Trials as Topic
Disease-Free Survival
Drug Approval / legislation & jurisprudence
Drug Approval / organization & administration
Humans
Neoplasms / drug therapy*
Neoplasms / mortality*
Sample Size
Survival Analysis
United States
United States Food and Drug Administration

Substances

Antineoplastic Agents
Biomarkers